Effect of propranolol on the splanchnic and peripheral renin angiotensin system in cirrhotic patients


AIM: To evaluate the effect of β-blockade on angiotensins in the splanchnic and peripheral circulation of cirrhotic patients and also to compare hemodynamic parameters during liver transplantation according to propranolol pre-treatment or not.

METHODS: Patients were allocated into two groups: outpatients with advanced liver disease (LD) and during liver transplantation (LT). Both groups were subdivided according to treatment with propranolol or not. Plasma was collected through peripheral venipuncture to determine plasma renin activity (PRA), Angiotensin (Ang) I, Ang II, and Ang-(1-7) levels by radioimmunoassay in LD group. During liver transplantation, hemodynamic parameters were determined and blood samples were obtained from the portal vein to measure renin angiotensin system (RAS) components.

RESULTS: PRA, Ang I, Ang II and Ang-(1-7) were significantly lower in the portal vein and periphery in all subgroups treated with propranolol as compared to non-treated. The relationships between Ang-(1-7) and Ang I levels and between Ang II and Ang I were significantly increased in LD group receiving propranolol. The ratio between Ang-(1-7) and Ang II remained unchanged in splanchnic and peripheral circulation in patients under β-blockade, whereas the relationship between Ang II and Ang I was significantly increased in splanchnic circulation of LT patients treated with propranolol. During liver transplantation, cardiac output and index as well systemic vascular resistance and index were reduced in propranolol-treated subgroup.

CONCLUSION: In LD group, propranolol treatment reduced RAS mediators, but did not change the ratio between Ang-(1-7) and Ang II in splanchnic and peripheral circulation. Furthermore, the modification of hemodynamic parameters in propranolol treated patients was not associated with changes in the angiotensin ratio.

© 2008 The WJG Press. All rights reserved.

Key words: β-blockade; Cirrhosis; Renin angiotensin system; Angiotensin-(1-7)

Peer reviewer: Mercedes Susan Mandell, MD, PhD, Department of Anesthesiology, University of Colorado Health Sciences Ctr., 12401 E. 17th Ave, B113 Aurora, CO 80045, United States

INTRODUCTION

The Renin-Angiotensin System (RAS) is a multilayered complex system. Previously, Angiotensin (Ang) II was thought to be the principle active peptide, exerting its action through type I and type II receptors. However, our understanding of the RAS has significantly
Additional active RAS peptides have been identified such as Ang III, with actions similar to Ang II and Ang IV, which exerts its activity at insulin-regulated amino peptide receptors, and Ang-(1-7), which acts mainly through Mas receptors. There is evidence that the RAS acts at the local tissue and even intracellular level through specific receptors by exerting paracrine, endocrine and intracrine functions. Further, the system mediates a variety of opposing physiological actions including vasoconstriction/vasodilation, fibrosis/antifibrosis and inflammation/anti-inflammatory. Therefore, the RAS is now viewed as a dual system composed of two arms: a vasoconstrictor arm formed by angiotensin converting enzyme (ACE)-Angiotensin (Ang) II-AT1 receptor and a vasodilator arm with ACE2-Ang-(1-7)-Mas receptor. The ACE2-Ang-(1-7)-Mas arm mainly acts as a counter-regulatory mechanism for the vasoconstrictor arm. According to this novel concept, the final functional effect of the RAS may reflect a balance between these two arms.

This novel view of the RAS makes the evaluation of this system in cirrhosis particularly challenging. In this regard, recent studies have suggested that the RAS seems to be involved in cirrhosis through its two main arms: the first (ACE-Ang II-AT1) by inducing liver fibrosis and maintaining the basal vascular tonus in cirrhosis and the second [ACE2-Ang-(1-7)-Mas] by exerting an anti-fibrotic role and probably by participating in the vasodilatation of cirrhosis.

Non-selective β-adrenergic blockers have been widely used in treatment of portal hypertension in cirrhosis. β-blockers lower portal pressure by reducing portal blood flow as a consequence of a decreased cardiac output (β1-receptor blockade) and arteriolar splanchnic vasoconstriction (β2-receptor blockade). β-blockers also inhibit renin secretion. However, the effect of propranolol on RAS mediators has still not been quantified, and neither have the hemodynamic changes that might occur during liver transplantation in cirrhotic patients pre-treated with propranolol. Since non-specific β blockade has been a standard approach to controlling the symptoms of portal hypertension and because the RAS seems to influence the outcome of portal hypertension and cirrhosis, it is reasonable to ask if there is a functional relationship between the RAS and beta-receptor system. For this purpose, we have taken in this study the first steps to understand how β1 and β2 blockade affects the RAS in cirrhotic patients. Thus, the aim of the present study was to compare the levels of plasma renin activity (PRA), Ang I, Ang II and Ang-(1-7), measured in the splanchnic and peripheral circulations of cirrhotic patients receiving or not propranolol and to evaluate the effect of previous administration of propranolol on hemodynamic parameters during liver transplantation.

**MATERIALS AND METHODS**

**Patients**

This cross-sectional study used a convenience sample recruited from either the Alfa Institute of Hepatology/Liver Transplantation or the Clinical Primary Care Center of our institution.

**Inclusion criteria**

Patients diagnosed with hepatic cirrhosis defined through liver histopathology and/or ultrasonography findings were included in this study. Tables 1 and 2 display the Child-Pugh and MELD scores of our patients (all patients were on the waiting list for liver transplantation). The etiology of the liver disease was established in the majority of the subjects (69%), and included alcoholism, virus C, virus B and bile cirrhosis. The cirrhotic patients were allocated to two study groups: one group was composed of patients who had advanced liver disease and were seen in an outpatient clinic (LD, \( n = 16 \)) and the second group was composed of liver transplant recipients during surgery (LT, \( n = 21 \)). Each

<table>
<thead>
<tr>
<th>Characteristics and measurements</th>
<th>LD with propranolol (( n = 9 ))</th>
<th>LD without propranolol (( n = 7 ))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>45 ± 2</td>
<td>54 ± 5</td>
</tr>
<tr>
<td>Sex male/female</td>
<td>5 (55.6%)/4 (44.4%)</td>
<td>4 (57%)/3 (43%)</td>
</tr>
<tr>
<td>Child Pugh Score</td>
<td>9.8 ± 0.5</td>
<td>11.0 ± 0.8</td>
</tr>
<tr>
<td>MELD Score</td>
<td>27.1 ± 1.3</td>
<td>29.3 ± 2.1</td>
</tr>
<tr>
<td>Albumin (g/dL)</td>
<td>2.7 ± 0.2</td>
<td>2.4 ± 0.3</td>
</tr>
<tr>
<td>Bilirubin (mg/dL)</td>
<td>2.5 (1.3-5.1)</td>
<td>2.5 (1.2-7.1)</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>1.2 (0.8-2.3)</td>
<td>1.0 (1.0-1.45)</td>
</tr>
<tr>
<td>INR (International Normalized Ratio)</td>
<td>1.62 (1.01-6.15)</td>
<td>1.55 (1.20-2.20)</td>
</tr>
<tr>
<td>Serum Na+ (mEq/L)</td>
<td>133.0 ± 1.6</td>
<td>126.0 ± 2.7</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SE or median (25 and 75 percentile), except for sex where number of patients and percentages are shown. \( P < 0.05 \) for the comparison of LD with propranolol and LD without propranolol (unpaired \( t \) test for mean comparisons and Mann-Whitney test for median comparisons).

<table>
<thead>
<tr>
<th>Characteristics and measurements</th>
<th>LT with propranolol (( n = 10 ))</th>
<th>LT without propranolol (( n = 11 ))</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (yrs)</td>
<td>50.6 ± 3.4</td>
<td>50.0 ± 2.6</td>
</tr>
<tr>
<td>Sex male/female</td>
<td>3 (30%)/7 (70%)</td>
<td>7 (63.6%)/4 (36.4%)</td>
</tr>
<tr>
<td>Child Pugh Score</td>
<td>10.5 ± 0.4</td>
<td>11.2 ± 0.6</td>
</tr>
<tr>
<td>MELD Score</td>
<td>28.0 ± 1.1</td>
<td>29.8 ± 1.6</td>
</tr>
<tr>
<td>Albumin (g/dL)</td>
<td>2.81 ± 0.09</td>
<td>2.61 ± 0.15</td>
</tr>
<tr>
<td>Bilirubin (mg/dL)</td>
<td>3.38 ± 1.20</td>
<td>3.70 ± 0.87</td>
</tr>
<tr>
<td>Creatinine (mg/dL)</td>
<td>1.0 (1.0-1.45)</td>
<td>1.05 (0.75-1.50)</td>
</tr>
<tr>
<td>INR (International Normalized Ratio)</td>
<td>1.36 (1.32-1.95)</td>
<td>1.69 (1.24-2.11)</td>
</tr>
<tr>
<td>Serum Na+ (mEq/L)</td>
<td>135.2 ± 1.0</td>
<td>130.1 ± 1.8</td>
</tr>
</tbody>
</table>

Data are expressed as mean ± SE or median (25 and 75 percentile), except for sex where number of patients and percentages are shown. \( P < 0.05 \) for the comparison of LT with propranolol and LT without propranolol (unpaired \( t \) test for mean comparisons and Mann-Whitney test for median comparisons).
of these two groups was further divided into patients who received propranolol and those who did not. The assistant physician was the only person responsible for the prescription and indication of propranolol treatment and the study protocol did not interfere with any medical prescriptions and recommendations. Thus, patients who were already on treatment with propranolol were then compared to those that did not receive treatment. As shown in Tables 1 and 2, the two subgroups of patients (treated vs non-treated) are comparable in the major demographic characteristics.

The LD group comprised outpatients with ascites and extra-hepatic complications such as encephalopathy and moderate to large esophageal varices (> 5 mm) with risk of bleeding. These patients were using diuretics (furosemide: 40-80 mg/d associated with spironolactone: 25-100 mg/d). Nine of these patients were also receiving propranolol for a mean period of 60 d (40-80 mg/d). The doses of propranolol were titrated to achieve a 20%-25% change in baseline heart rate.

The LT group included hospitalized cirrhotic patients with the same severity of liver disease as compared to LD group based on Child Pugh and MELD scores (Child Pugh: 11.0 ± 0.8 in LD vs 11.2 ± 1.2 in LT and MELD: 29.3 ± 2.1 in LD vs 29.8 ± 3.2 in LT, \( P > 0.05 \) for both comparisons). These patients also presented the same clinical and laboratorial features as the LD group and received the same diuretic treatment. The only difference between both groups is the fact that LT patients have been submitted to liver transplantation. Ten of the LT patients were using propranolol (40-80 mg/d) until the time of liver transplantation and their doses were also titrated to achieve a 20%-25% change in baseline heart rate.

Exclusion criteria
Co-morbidities such as diabetes, heart, pulmonary, autoimmune and neurological diseases automatically excluded subjects from the study. Patients receiving chronic treatment with angiotensin-converting enzyme inhibitors, angiotensin receptor blockers, renin inhibitors and corticosteroids were also excluded from the study. During liver transplantation, blood collection was suspended whenever the subject presented acute hemodynamic disarrangements and needed to use a vasoconstrictor.

Ethical aspects
The Ethics Committee of the Federal University of Minas Gerais approved the study. Informed consent was obtained from all included subjects. The research protocol did not interfere with any medical recommendations or prescriptions. Subject follow-up was guaranteed even in cases of refusal to participate in the study.

Study protocol
Protocol 1 - Evaluation of circulating RAS in outpatients using or not using propranolol: Blood samples for PRA and angiotensin measurements were obtained from LD patients on a single occasion taking into account the inclusion and exclusion criteria for each group. Due to ethical reasons, no changes to the clinical approach were made for study purposes. Blood samples (10 mL) were collected through peripheral venipuncture in the morning after a fasting period of 8 h. All subjects rested in supine position for at least 30 min before blood sampling.

Protocol 2 - Evaluation of RAS and hemodynamic parameters during pre-anhepatic stage of liver transplantation in patients pre-treated with propranolol or not: In the LT group, blood sampling was performed during the pre-anhepatic stage of liver transplantation and samples were obtained from the portal vein (10 mL) to evaluate RAS mediators. Hemodynamic parameters (cardiac output, cardiac index, systemic vascular resistance and systemic vascular resistance index) were determined simultaneously with the blood sampling. These measurements were obtained through invasive continuous monitoring \( siu \) a Swan-Ganz catheter (CCOMBO/SVO2, 110 cm/7.5 F, Edwards Lifesciences, Irvine, CA, USA), using Dixtal (DX 2020, Dixtal Biomedical, São Paulo, Brazil) and Vigilance (CEDV, Edwards Lifesciences, Irvine, CA, USA) monitors. Anesthesia for liver transplantation was induced by a rapid sequence of etomidate, fentanyl and succinylcholine and maintained by isoflurane (CAM~1.0) and atracurium until the blood sampling.

Blood collection: For all blood collections, samples were drawn into two sets of ice-cooled tubes-one containing 7.5% EDTA for PRA determinations and the other containing a cocktail of protease inhibitors for angiotensin measurements, as previously described[14]. Blood samples were centrifuged at \( \times 2000 \) g for 20 min at 4°C and plasma stored at -20°C[15].

Plasma extraction and radioimmunoassays: Plasma samples were extracted using Bond-Elut cartridges (Analytichem International, Harbor City, CA), as described elsewhere[15]. PRA as well as Ang I, Ang II and Ang-(1-7) concentrations were determined through radioimmunoassays, as detailed elsewhere[15]. The recovery of \( ^{125}I \)-labeled Ang I, Ang II, and Ang-(1-7) was 79.2% ± 2.3%, 86.9% ± 0.8% and 83.5% ± 0.9%, respectively. Results were expressed as nanograms of Ang I generated per mL of plasma per hour (ng Ang I/mL per hour) for PRA and pg/mL of plasma for Ang measurements.

Statistical analysis
Gaussian distribution of variables was evaluated by the Shapiro normality test. Results were reported as mean ± SE or median, when appropriate. Unpaired \( t \) test was used for the comparison of means between groups. Mann-Whitney was used to compare non-parametric
Peripheral and splanchnic circulating RAS profile in LD and LT patients pre-treated with propranolol or not

As displayed in Figure 1, PRA and angiotensin I (Ang I) were lower in peripheral circulation of the LD group treated with propranolol in comparison to LD group not receiving propranolol (PRA: 3.54 ± 1.35 ng Ang I/mL per hour vs 79.8 ± 24.8 pg/mL, P < 0.05 for both comparisons). As shown in Figure 2, the same profile was observed for the LT group pre-treated with propranolol, which also presented a significant reduction of the PRA and Ang I plasma levels in the portal vein when compared to the LT group that was not treated with propranolol (PRA: 2.20 ± 0.51 ng Ang I/mL per hour vs 7.4 ± 0.30 ng Ang I/mL per hour; Ang I: 764.2 ± 117.0 pg/mL vs 235.0 ± 75.6 pg/mL, P < 0.05 for both comparisons).

LD patients receiving propranolol also exhibited a significant reduction in the levels of Ang II in peripheral circulation when compared to LD patients not using propranolol (Ang II: 117.2 ± 33.5 pg/mL vs 53.9 ± 6.5 pg/mL, P < 0.05, Figure 1). The same reduction of Ang II levels was observed in splanchnic circulation (portal vein) of the LT group under β-blockade in comparison to LT group not treated with propranolol (Ang II: 143.4 ± 13.5 pg/mL vs 96.9 ± 12.6 pg/mL, P < 0.05, Figure 2). Plasma levels of Ang-(1-7) were also reduced in splanchnic circulation of the LT group that was previously treated with propranolol in comparison to non-treated LT group (62.3 ± 10.9 pg/mL vs 35.5 ± 3.8 pg/mL, P < 0.05, Figure 2), whereas plasma Ang-(1-7) in peripheral circulation of the LD group did not differ significantly despite treatment or not with propranolol (Figure 1).

Ratios between Ang-(1-7) and Ang I levels, between Ang II and Ang I, and between Ang-(1-7) and Ang II in LD and LT groups are displayed in Tables 3 and 4, respectively. The ratio between Ang-(1-7) and Ang I indirectly reflects ACE2 activity, whereas the
ratio between Ang II and Ang I indirectly estimates ACE activity. Both ratios were significantly increased in peripheral circulation of the LD group using propranolol in comparison to LD patients not receiving the β-blocker (P < 0.01, Table 3). Only Ang II/Ang I ratio was increased in splanchnic circulation of the LT group pre-treated with propranolol in comparison to LT patients that had not received propranolol (P < 0.01, Table 4), whereas Ang-(1-7)/Ang I did not significantly differ in splanchnic circulation of LT patients despite the previous treatment or not with propranolol. More importantly, the ratio between Ang-(1-7) and Ang II, which could represent the final functional relationship between RAS mediators, did not differ in either peripheral circulation of the LD group or in splanchnic circulation of the LT group, independently of the previous use or not of the β-blocker.

**Hemodynamic parameters during pre-anhepatic stage of liver transplantation in LT pre-treated with propranolol or not**

In order to demonstrate that our LT patients pre-treated with propranolol were adequately β blocked, we measured hemodynamic parameters during pre-hepatic stage of liver transplantation. Accordingly, in LT patients pre-treated with propranolol, the cardiac output (8.9 ± 0.9 L/min vs 5.6 ± 0.6 L/min) and cardiac index (4.7 ± 0.4 L/min per m² vs 3.2 ± 0.3 L/min per m²) were reduced and the systemic vascular resistance (604.2 ± 65.0 × 877.5 ± 106.1 dyn.s/cm²) and its index [(1036 ± 86) × (1399 ± 147)] dyn.s/cm² per m²) were increased in comparison to patients that had not previously received propranolol (P < 0.05 for all comparisons, Figure 3).

**DISCUSSION**

In general, our data showed that chronic treatment with propranolol in cirrhotic patients is characterized by marked changes in the precursors of RAS cascade (Renin and Ang I) with repercussion in RAS two main arms at the splanchnic and peripheral circulation. On the other hand, no changes were detected in the ratio between the two main RAS mediators [Ang-(1-7)/Ang II], which has been used to evaluate the final functional effect of the RAS. In parallel, the chronic use of propranolol produced hemodynamic changes, which were probably able to control the hyperdynamic circulation of cirrhotic patients. Taken together, these findings suggest that the reduction of hyperdynamic circulation produced by chronic treatment with propranolol in cirrhotic patients was associated with an overall RAS inhibition, but it was not due to changes in the balance between the two RAS arms: ACE-Ang-AT1 (vasoconstrictor) versus ACE2-Ang-(1-7)-Mas (vasodilator).

In splanchnic and peripheral circulation, the β-blockade in cirrhotic patients was characterized by reduced PRA and Ang I levels. These RAS components can lead to the synthesis of both Ang II and Ang-(1-7) [5,16]. The cirrhotic patients receiving propranolol have reduced Ang II levels in the splanchnic and in the peripheral circulation as well as reduced Ang-(1-7) levels in the splanchnic circulation. In this regard, Blumenfeld et al[23] previously suggested that β-blockade reduced Ang II levels and PRA in normotensive and hypertensive subjects by inhibiting prorenin processing to renin.
Ratios between angiotensins, especially the relationship between Ang-(1-7) and Ang II, have been used to estimate the final functional RAS effect[23,34]. In this study, propranolol use was not able to change the ratio between Ang-(1-7) and Ang II in splanchnic and peripheral circulation of non-compensated cirrhotic patients, although there was an absolute decrease in both angiotensins. In parallel, systemic vascular resistance (SVR) and its index increased and cardiac output (CO) and its index decreased in non-compensated cirrhotic patients treated with propranolol. Similar hemodynamic changes in cirrhotic patients receiving propranolol have already been reported[17-19] and attributed to β-adrenergic blockade[20]. Since the relationship between Ang-(1-7) and Ang II remained unchanged in splanchnic and peripheral circulation of our cirrhotic patients, we could hypothesize that propranolol was not able to interfere with the final functional RAS effect upon vascular tone. Our data also suggest that the activity of the two main RAS enzymes, ACE and ACE2, were probably not reduced by propranolol use in cirrhotic patients, since the ratios between Ang II and Ang I and between Ang-(1-7) and Ang I were increased in peripheral circulation and the ratio between Ang II and Ang I was also elevated in splanchnic circulation. However, we can not exclude the possibility that other factors such as changes in the catabolism of Ang II or Ang-(1-7) could have contributed to the reduction in absolute levels of each peptide.

In cirrhotic patients, arteriolar vasodilation and diuretic administration cause a decreased effective arterial blood volume that stimulates vasopressor systems leading to high levels of PRA, circulating norepinephrine, and vasopressin[21-23]. In this context, propranolol inhibits renin secretion and reduces vasodilation (SVR increase) in cirrhosis[37], leading to a reduction of the relative arterial hypovolemia. These actions could oppose the activated vasopressor systems (RAS, sympathetic nervous system and vasopressin) and may be involved in the amelioration of the hyperdynamic circulation observed in our cirrhotic patients.

It should also be pointed out that we are aware of the limitations of our study design. For example, peripheral blood samples generally represent the cumulative expression of RAS in multiple tissues and may not reliably reflect molecular activity in the splanchnic circulation. For this reason, we did manage to collect samples from the portal vein during liver transplantation. However, it is still difficult to compare these findings to the samples collected in peripheral blood from outpatients. Nevertheless, some aspects of this study may increase the strength of our findings, such as the utilization of strictly defined inclusion and exclusion criteria and the well-established protocol for the measurements of PRA and angiotensins[38].

In conclusion, results obtained with propranolol treatment in cirrhotic patients have been controversial[30,24]. While in advanced liver disease with significant reduction of the hepatic venous pressure gradient propranolol treatment decreased the risk of ascites, spontaneous bacterial peritonitis, hepatorenal syndrome and death[24], in unselected cirrhotic patients the same β-blocker was not able to prevent varices and was associated with an increased number of adverse events[20]. We believe that the use of propranolol in cirrhosis could change the prognosis of patients with hyperdynamic circulation and relative hypovolemia, but it is probably not able to interfere with potentially reversible liver fibrosis. Indeed, the use of propranolol did not alter the balance between the activity of the anti-fibrotic arm of the RAS, ACE2-Ang-(1-7)-Mas[39], and of the pro-fibrotic arm, ACE-Ang II-AT1[40]. For this purpose, many studies have suggested that ACE inhibitors and AT1 receptor blockers seemed to be effective[25-29]. Their mechanisms of action probably involve not only the inhibition of Ang II formation or action but also the augmentation of Ang-(1-7) levels or effects[6,29]. On the other hand, it should be mentioned that, mostly in advanced stages of cirrhosis, the ACE-Ang II-AT1 arm contributes to the maintenance of basal vascular tonus[7] and therefore the use of AT1 receptor blockers or ACE inhibitors as antifibrotic therapies could not be well tolerated. Since propranolol administration seems to improve only the extrahepatic complications of the advanced cirrhotic patients, a possible therapeutic approach for human cirrhosis at this stage could be the combination of AT1 receptor blockers or ACE inhibitors with propranolol. Future studies with more powerful designs are obviously necessary to evaluate whether the use of propranolol at this stage of cirrhosis would enable the administration of AT1 receptor blockers or ACE inhibitors or even receptor Mas agonists to reduce liver fibrosis.

COMMENTS

Background
Recent studies have suggested that the Renin Angiotensin System (RAS) seems to be involved in cirrhosis. Non-selective β-adrenergic blockers have been widely used in treatment of portal hypertension in cirrhosis. However, the effect of propranolol on RAS mediators has not still been quantified. Since non-specific β blockade has been a standard approach to controlling the symptoms of portal hypertension and because the RAS seems to influence the outcome of portal hypertension and cirrhosis, it is reasonable to ask if there is a functional relationship between the RAS and beta-receptor system.

Research frontiers
This study represents an initial approach in understanding how non-specific β blockade affects RAS in cirrhotic patients by comparing the levels of plasma renin activity, Angiotensin (Ang) I, Ang II and Ang-(1-7), measured in the splanchnic and peripheral circulations of cirrhotic patients receiving or not receiving propranolol and by evaluating the effect of previous administration of propranolol on hemodynamic parameters during liver transplantation.

Innovations and breakthroughs
Chronic treatment with propranolol in cirrhotic patients is characterized by marked changes in the precursors of RAS cascade (Renin and Ang I) with repercussion in RAS two main arms in the splanchnic and peripheral circulation. On the other hand, no changes were detected in the ratio between the two main RAS mediators [Ang-(1-7)/Ang II]. Additionally, the treatment with propranolol seemed to be able to control the hyperdynamic circulation of cirrhotic patients probably due to an overall RAS inhibition, but without changes in the balance between the two RAS arms: ACE-Ang-Ang-(1-7)-Mas (vasoconstrictor) versus ACE2-Ang-(1-7)-Mas (vasodilator).

Applications
Our data suggest that a possible therapeutic approach for advanced human cirrhosis could be the combination of AT1 receptor blockers or ACE inhibitors...
with propranolol. Future studies with more powerful designs are obviously necessary to evaluate whether the use of propranolol at this stage of cirrhosis would enable the administration of AT1 receptor blockers or ACE inhibitors or even receptor Mas agonists to reduce liver fibrosis.

**Peer review**

In the current study, the investigators have taken the first steps to understand how β1 and β2 blockade affects RAS in patients. This is important because non-specific β blockade has been a standard approach to controlling the symptoms of portal hypertension.

**REFERENCES**


S- Editor Cheng JX  L- Editor Logan S  E- Editor Yin DH